Skip to main content

Cryolipolysis — Suprapubic Fat Reduction

Cryolipolysis is a noninvasive, FDA-cleared technology that uses controlled cooling to selectively destroy subcutaneous adipocytes without damaging overlying skin or surrounding structures. When applied to the suprapubic region, it serves as a nonsurgical alternative to liposuction for reducing the fat pad that buries the penile shaft. One prospective study (Azab 2021, n = 46) specifically demonstrated increased apparent penile length through three sessions of suprapubic cryolipolysis.[1]

For the broader male cosmetic-genital-surgery decision framework see the Male Cosmetic Genital Surgery atlas page. For the surgical alternative — direct fat-pad excision — see Suprapubic Lipectomy. For the broader buried-penis condition see Adult-Acquired Buried Penis.

I. Definition and Concept​

Cryolipolysis exploits the observation that lipid-rich adipocytes are more susceptible to cold injury than surrounding water-rich cells (skin, nerves, vasculature). A cup-shaped applicator draws a fold of skin and subcutaneous fat between two cooling plates, lowering tissue temperature to approximately −10°C to −11°C for 35–60 minutes. This induces crystallization of cytoplasmic lipids within adipocytes, triggering a cascade of apoptosis, panniculitis, and gradual adipocyte clearance over 2–4 months.[2][3][4]

The concept derives from the clinical observation of "popsicle panniculitis" — cold-induced fat necrosis in children's cheeks from prolonged cold exposure — first described decades before the technology was developed.[4]

II. Mechanism of Action​

The mechanism proceeds through a well-characterized sequence.[2][5][6][7][8]

  1. Cooling phase — tissue temperature drops to ~ 0°C to −10°C; subdermal temperatures decline precipitously within 30 minutes.[9]
  2. Lipid crystallization — cytoplasmic lipids within adipocytes crystallize at temperatures that do not damage water-rich cells (skin, nerves, vessels).
  3. Adipocyte membrane disruption — crystallization causes loss of cellular integrity and membrane disruption, evident histologically in all treated areas.[5]
  4. Apoptosis initiation — cold-induced apoptosis (not necrosis) is the primary cell-death pathway, though some necrosis also occurs.[6][8]
  5. Inflammatory panniculitis — an inflammatory infiltrate of immune cells (macrophages, lymphocytes) appears at the treatment site within 2–3 days, peaking at 14–30 days.[7][8]
  6. Phagocytic clearance — macrophages engulf lipid debris and dead adipocytes; this process occurs gradually over 2–4 months.[4][8]
  7. Connective-tissue remodeling — focal dissolution and homogenization of collagen fibers with dissolution of interlobular fibrous septa; neocapillarization observed at 45–60 days.[5]
  8. Fat-layer reduction — clinically measurable decrease in fat thickness, typically 20–25% after a single treatment.[3][9]

Additional mechanisms. Recent evidence suggests cryolipolysis may also promote conversion of white adipocytes to brown / beige adipocytes ("browning"), with increased expression of UCP-1, PPAR-γ, and PPAR-α markers in treated tissue, potentially contributing to additional metabolic effects.[6]

Selectivity. The key safety feature is that adipocytes are selectively damaged while skin, nerves, blood vessels, and muscle are spared. This selectivity is based on the higher freezing point of lipids vs water-rich tissues.[2][4][8]

III. FDA Clearance History​

Cryolipolysis (CoolSculpting, originally ZELTIQ Aesthetics, now Allergan / AbbVie) has received sequential FDA clearances for multiple body areas.[2][10][11][12]

  • 2010 — flanks (love handles); initial FDA clearance.[12]
  • 2011 — abdomen.[2]
  • 2014 — inner and outer thighs.[11]
  • 2015 — submental area (double chin).[10]
  • Subsequent clearances for upper arms, back / bra fat, banana roll (infragluteal), and lateral thighs.
Off-label suprapubic application

The suprapubic / mons-pubis region is not specifically FDA-cleared for cryolipolysis. Treatment of this area represents off-label use of the device, though applicators designed for the abdomen or small areas (CoolMini) can be adapted.[1][13]

IV. Suprapubic Application — The Key Study​

Azab 2021 is the only published study specifically evaluating cryolipolysis for suprapubic fat reduction to increase apparent penile length.[1]

  • Design. Prospective, n = 46 males.
  • Population. Men complaining of "buried short apparent small-size penis" due to suprapubic fat.
  • Protocol. Three consecutive suprapubic cryolipolysis sessions.

Results. Mean apparent stretched penile length increased progressively:

SessionApparent SPL
Baseline → after Session 112.10 → 12.10 ± 0.5 cm
After Session 212.66 ± 0.48 cm
After Session 312.88 ± 0.72 cm
Total gain~ 0.78 cm (statistically significant, p < 0.05)

Suprapubic fat-thickness reduction was approximately 33% across the three sessions. No serious adverse events were reported.[1]

The Mineroff 2023 narrative review of suprapubic-adiposity treatment modalities frames Azab 2021 as the foundational suprapubic-cryolipolysis evidence base and notes that no head-to-head comparison with liposuction exists.[13]

V. General Efficacy Data (All Body Sites)​

Fat-reduction measurements​

Per the most recent SR / meta-analysis (Ravindran 2025; 30 studies, 3,158 participants), at 12 weeks post-treatment.[14]

  • BMI reduction — MD −1.80 (95% CI −2.98 to −0.62; p = 0.0003).
  • Waist-to-hip ratio reduction — MD −0.09 (95% CI −0.16 to −0.02; p = 0.001).
  • Abdominal-circumference reduction — MD −3.56 cm (95% CI −4.98 to −2.15; p < 0.001).
  • Average reduction in caliper measurement — 14.67–28.5%.[3]
  • Average reduction by ultrasound — 10.3–25.5%.
  • No significant impact on lipid levels or liver function tests.

Patient satisfaction​

  • 80.4% overall satisfaction rate (meta-analysis).[14]
  • 89.6% "satisfied" or "very satisfied" in the largest prospective PRO study (n = 112).[15]
  • 93.4% would recommend to a friend.[15]
  • 90.6% reported "noticeable" or "very noticeable" fat reduction.[15]

Multiple treatments​

McKeown & Payne 2021 demonstrated that ≥ 3 cycles produced significantly greater skinfold reduction than 1–2 cycles (mean reduction 40% with multiple cycles), with 88% satisfaction.[16]

VI. Treatment Protocol​

Standard treatment parameters.[2][3][9][17][18]

  • Temperature — approximately −10°C to −11°C.
  • Duration — 35–60 minutes per cycle (newer applicators achieve equivalent results in 35 minutes).[18]
  • Applicator selection — vacuum cup-shaped applicators of various sizes; flat-cup applicators for inner thighs and arms; small applicators (CoolMini) for submental and small areas.
  • Post-treatment massage — 2 minutes of vigorous manual massage immediately after applicator removal — Boey 2014 demonstrated this enhances efficacy by 44–68% compared to non-massaged sites at 2–4 months.[19]
  • Number of sessions — 1–3 sessions per area, spaced 4–8 weeks apart.
  • Results timeline — gradual fat reduction over 2–4 months, with maximum effect at 3–6 months.[4][9][20]

For the suprapubic application (extrapolated from Azab and general protocols).[1]

  • Applicator placed over the suprapubic fat pad (mons-pubis region).
  • Standard cooling parameters (−10°C, 35–60 minutes).
  • Three sessions recommended for optimal results.
  • Post-treatment massage of the treated area.
  • Care to avoid proximity to the penile shaft and scrotal structures.

Newer dual-applicator systems (CoolSculpting Elite) allow simultaneous bilateral treatment, reducing total procedure time. Geronemus 2025 multicenter study (n = 110) demonstrated 83.3% satisfaction with midsection results and mean fat-volume loss of 194.8 mL.[21]

VII. Adverse Events​

Common (minor, self-limiting)​

Per the 2025 meta-analysis (Ravindran).[14]

EventIncidence
Numbness / paresthesia49.5%
Erythema44.5%
Edema30.5%
Pain28.8%
Sensitivity25.4%
Tingling15.2%
Hyperpigmentation2%

Most adverse events resolve within 1–4 weeks; numbness may persist for approximately 3 months.[22] A 2026 prospective study (n = 1,553 treatment areas) confirmed that the overall AE rate decreased from 71.6% immediately post-treatment to 1.3% at 3 months.[22]

Serious / rare complications​

Per Hedayati 2020 SR (53 articles).[23]

  • Severe / persistent pain — rare; may last weeks to months.
  • Dysesthesia — altered sensation at the treatment site.
  • Motor neuropathy — extremely rare case reports.
  • Skin hyperpigmentation — more common in darker skin types.
  • Contour irregularities — indentations, asymmetries, soft-tissue atrophy.[24]
  • Paradoxical adipose hyperplasia (PAH) — the most clinically significant rare complication (see below).

Paradoxical adipose hyperplasia (PAH)​

PAH is characterized by abnormal enlargement of the treatment area occurring 2–5 months after cryolipolysis, with the treated fat becoming a well-demarcated, firm subcutaneous mass that exceeds the original volume.[2][25][26][27][28]

Incidence. Initially reported at 0.0051% (Jalian 2014); subsequent studies suggest the true incidence is substantially higher.[2][27]

  • 0.05–0.39% per treatment cycle (Nikolis 2021 multicenter, 8,658 cycles).[27]
  • 0.67% per patient at one academic center (Cox 2022).[25]
  • Likely underreported overall.[12][26]

Risk factors.[2][25][27]

  • Male sex — PAH appears more common in males (55% of cases in the Nikolis series). This is the salient risk factor for the suprapubic-cryolipolysis patient.
  • Older device models — 76.9% of PAH cases were associated with older CoolSculpting units; incidence reduced by > 75% with newer models.[27]
  • European ethnic origin — 77.8% of cases.[27]
  • No single unifying risk factor identified.[2]

Pathophysiology. Unknown. Histology shows nonspecific panniculitis.[28] One hypothesis suggests that some adipocytes may be "naturally selected" for survival due to inherent cold tolerance, and the inflammatory response may stimulate adipogenesis or hypertrophy in surviving cells.[12]

Management.[25][26][28]

  • Does not spontaneously resolve in most cases (though 3 of 4 patients in one series stabilized without treatment).[2][28]
  • Requires surgical correction — liposuction, abdominoplasty, or both.[25][26]
  • Surgical treatment is effective with no recurrence reported in treated patients.[25]

VIII. Contraindications​

Absolute.[23][29]

  • Cryoglobulinemia.
  • Cold agglutinin disease.
  • Paroxysmal cold hemoglobinuria.
  • Cold urticaria.

Relative.[23][29]

  • Raynaud disease — though Yanes 2021 found no exacerbations in patients with mild–moderate Raynaud disease treated with cryolipolysis.[29]
  • Scars or hernias in the treatment area.
  • Impaired skin sensation in the treatment area.
  • Open or infected wounds.
  • Dermatitis or eczema in the treatment area.
  • Pregnancy.

Suprapubic-specific considerations.

  • Proximity to the penile shaft and scrotum — applicator placement must avoid direct cooling of genital structures.
  • Thin suprapubic skin in lean patients may increase the risk of skin injury.
  • No published safety data specific to the suprapubic region beyond Azab 2021.

IX. Comparison: Cryolipolysis vs Suprapubic Lipectomy​

FeatureCryolipolysisSuprapubic Lipectomy
InvasivenessNoninvasiveMinimally invasive (surgical)
AnesthesiaNone requiredLocal ± sedation, or general
Fat reduction per session15–25%50–80% (immediate)
Number of sessions1–3+ for optimal resultsUsually 1
DowntimeNone (return to activities immediately)1–2 weeks
Results timelineGradual over 2–4 monthsImmediate (swelling resolves 4–6 weeks)
Apparent penile length gain~ 0.78 cm (Azab 2021, 3 sessions)1–2 cm (estimated)
Suprapubic fat reduction~ 33% (Azab 2021, 3 sessions)50–80%
ComplicationsMinor (numbness, erythema); PAH rare but male-predominantHematoma, seroma, contour irregularity, infection
Skin tighteningNone (may worsen laxity)None (may worsen laxity)
FDA status for suprapubicOff-labelNot FDA-regulated (surgical)
Published suprapubic evidence1 study, n = 46 (Azab 2021)Multiple case series

X. Systemic Safety​

An important safety feature of cryolipolysis is the absence of systemic metabolic effects.[3][4][8]

  • No significant changes in serum lipids (cholesterol, triglycerides) after treatment in any published study.
  • No changes in liver function tests.
  • Gradual phagocytic clearance of adipocyte debris avoids the bolus lipid release that could theoretically affect hepatic or cardiovascular function.
  • No scarring, ulceration, or permanent skin damage reported in standard use.[4]

XI. Limitations and Evidence Quality​

Several caveats apply to the cryolipolysis literature.[13][30]

  • Commercial bias. Many studies are industry-sponsored or conducted by investigators with financial relationships with device manufacturers. Atiyeh 2020 raised "serious concerns about integrity of many of these reports, particularly with respect to validity of photographic outcome documentation in addition to objectivity, conflict of interest issues, and commercial bias."[30]
  • Lack of rigorous methodology. Most studies are single-arm, uncontrolled, with subjective outcome measures (photographs, patient satisfaction). Few RCTs exist.[30]
  • Suprapubic data extremely limited. Only one study (Azab 2021, n = 46) has evaluated suprapubic cryolipolysis — no control group, no long-term follow-up, modest length gains (~ 0.78 cm).[1]
  • No head-to-head comparisons with liposuction for the suprapubic area exist.[13]
  • Not a weight-loss procedure. Cryolipolysis is designed for localized fat reduction in patients near ideal body weight with discrete, pinchable fat bulges — not effective for generalized obesity or large-volume fat reduction.[3][4]

XII. Clinical Summary​

Cryolipolysis is a well-established, FDA-cleared noninvasive technology for localized fat reduction, with robust evidence supporting 15–25% fat-layer reduction per session across multiple body sites, 80–90% patient satisfaction, and a favorable safety profile dominated by minor, self-limiting adverse events.[3][14][15] The most significant rare complication is paradoxical adipose hyperplasia (PAH), occurring in approximately 0.05–0.67% of cases — more common in males, requiring surgical correction.[25][27] The male-predominance of PAH is the salient counseling point for the suprapubic-cryolipolysis patient.

For suprapubic fat reduction and apparent penile-length augmentation, cryolipolysis represents a promising but minimally studied noninvasive alternative to liposuction. Azab 2021 (n = 46) demonstrated a statistically significant ~ 1 cm reduction in suprapubic fat thickness and ~ 0.78 cm increase in apparent penile length after three sessions, with no serious adverse events.[1] These gains are modest compared to suprapubic lipectomy, and the suprapubic area is not specifically FDA-cleared for cryolipolysis.[13] The procedure is best suited for men with mild-to-moderate suprapubic adiposity who prefer a noninvasive approach and accept the need for multiple sessions and more modest results compared to surgical alternatives.

See Also​

References​

1. Azab SS, Hamed HA, Elseginy A, Elzawahry HM, Ismail NN. Increase apparent penile length by cryolipolysis in the reduction of male suprapubic fat. Andrologia. 2021;53(3):e13963. doi:10.1111/and.13963

2. Jalian HR, Avram MM, Garibyan L, Mihm MC, Anderson RR. Paradoxical adipose hyperplasia after cryolipolysis. JAMA Dermatol. 2014;150(3):317–319. doi:10.1001/jamadermatol.2013.8071

3. Ingargiola MJ, Motakef S, Chung MT, Vasconez HC, Sasaki GH. Cryolipolysis for fat reduction and body contouring: safety and efficacy of current treatment paradigms. Plast Reconstr Surg. 2015;135(6):1581–1590. doi:10.1097/PRS.0000000000001236

4. Nelson AA, Wasserman D, Avram MM. Cryolipolysis for reduction of excess adipose tissue. Semin Cutan Med Surg. 2009;28(4):244–249. doi:10.1016/j.sder.2009.11.004

5. Pugliese D, Melfa F, Guarino E, et al. Histopathological features of tissue alterations induced by cryolipolysis on human adipose tissue. Aesthet Surg J. 2020;40(7):761–766. doi:10.1093/asj/sjaa035

6. Palauro CRT, Meyer PF, Soares CD, et al. Effects of cryolipolysis on the conversion of white adipose tissue: pilot study. Lasers Surg Med. 2025;57(1):88–95. doi:10.1002/lsm.23839

7. Salma N, Wang-Evers M, Casper MJ, et al. Mouse model of selective cryolipolysis. Lasers Surg Med. 2023;55(1):126–134. doi:10.1002/lsm.23573

8. Zelickson B, Egbert BM, Preciado J, et al. Cryolipolysis for noninvasive fat-cell destruction: initial results from a pig model. Dermatol Surg. 2009;35(10):1462–1470. doi:10.1111/j.1524-4725.2009.01259.x

9. Sasaki GH, Abelev N, Tevez-Ortiz A. Noninvasive selective cryolipolysis and reperfusion recovery for localized natural fat reduction and contouring. Aesthet Surg J. 2014;34(3):420–431. doi:10.1177/1090820X13520320

10. Kilmer SL, Burns AJ, Zelickson BD. Safety and efficacy of cryolipolysis for non-invasive reduction of submental fat. Lasers Surg Med. 2016;48(1):3–13. doi:10.1002/lsm.22440

11. Zelickson BD, Burns AJ, Kilmer SL. Cryolipolysis for safe and effective inner thigh fat reduction. Lasers Surg Med. 2015;47(2):120–127. doi:10.1002/lsm.22320

12. Ho D, Jagdeo J. A systematic review of paradoxical adipose hyperplasia (PAH) post-cryolipolysis. J Drugs Dermatol. 2017;16(1):62–67.

13. Mineroff J, Nguyen JK, Jagdeo J. Potential treatment modalities for suprapubic adiposity and pubic contouring. Arch Dermatol Res. 2023;315(6):1615–1619. doi:10.1007/s00403-023-02555-z

14. Ravindran R, Pizzol D, Rahmati M, et al. Cryolipolysis and associated health outcomes, adverse events, and satisfaction: a systematic review and meta-analysis. Obes Rev. 2025;26(8):e13925. doi:10.1111/obr.13925

15. Tan T, Snell B, Braun M, et al. High participant satisfaction achieved using cryolipolysis for fat reduction of the abdomen and flanks. Aesthet Surg J. 2022;42(7):760–770. doi:10.1093/asj/sjab421

16. McKeown DJ, Payne J. Significant improvement in body contour with multiple cycles of CoolSculpting: results of a prospective study. Dermatol Ther. 2021;34(2):e14850. doi:10.1111/dth.14850

17. Brassolatti P, de Andrade ALM, Nishioka MA, et al. The clinical impact of different cryolipolysis protocols: an integrative review. Aesthet Plast Surg. 2025. doi:10.1007/s00266-025-04864-2

18. Kilmer SL. Prototype CoolCup cryolipolysis applicator with over 40% reduced treatment time demonstrates equivalent safety and efficacy with greater patient preference. Lasers Surg Med. 2017;49(1):63–68. doi:10.1002/lsm.22550

19. Boey GE, Wasilenchuk JL. Enhanced clinical outcome with manual massage following cryolipolysis treatment: a 4-month study of safety and efficacy. Lasers Surg Med. 2014;46(1):20–26. doi:10.1002/lsm.22209

20. Coiante E, Pensato R, Hadji I, et al. Assessment of the efficacy of cryolipolysis on abdominal fat deposits: a prospective study. Aesthet Plast Surg. 2023;47(6):2679–2686. doi:10.1007/s00266-023-03369-0

21. Geronemus RG, Wang JV, Goldman MP, et al. Participant satisfaction, effectiveness, and safety with a novel dual-applicator cryolipolysis system: a prospective, multicountry study. Dermatol Surg. 2025. doi:10.1097/DSS.0000000000004797

22. Nishikawa A, Aikawa Y, Kono T. Adverse events associated with cryolipolysis treatment for body contouring: a prospective observational study with 3-month follow-up. Plast Reconstr Surg. 2026;157(4):532e–540e. doi:10.1097/PRS.0000000000012406

23. Hedayati B, Juhász M, Chu S, Mesinkovska NA. Adverse events associated with cryolipolysis: a systematic review of the literature. Dermatol Surg. 2020;46(Suppl 1):S8–S13. doi:10.1097/DSS.0000000000002524

24. Khan M. Complications of cryolipolysis: paradoxical adipose hyperplasia (PAH) and beyond. Aesthet Surg J. 2019;39(8):NP334–NP342. doi:10.1093/asj/sjy282

25. Cox EA, Nichols DS, Riklan JE, et al. Characteristics and treatment of patients diagnosed with paradoxical adipose hyperplasia after cryolipolysis: a case series and scoping review. Aesthet Surg J. 2022;42(12):NP763–NP774. doi:10.1093/asj/sjac219

26. Stein MJ, Smith D, Chia C, Matarasso A. Paradoxical adipose hyperplasia following cryolipolysis. Aesthet Surg J. 2024;44(10):1063–1071. doi:10.1093/asj/sjae077

27. Nikolis A, Enright KM. A multicenter evaluation of paradoxical adipose hyperplasia following cryolipolysis for fat reduction and body contouring: a review of 8658 cycles in 2114 patients. Aesthet Surg J. 2021;41(8):932–941. doi:10.1093/asj/sjaa310

28. Stroumza N, Gauthier N, Senet P, et al. Paradoxical adipose hypertrophy (PAH) after cryolipolysis. Aesthet Surg J. 2018;38(4):411–417. doi:10.1093/asj/sjx159

29. Yanes D, Sawaya J, Wanner M, Avram M. Predicting negative outcomes of cryolipolysis in patients with and without Raynaud disease. Dermatol Surg. 2021;47(5):675–677. doi:10.1097/DSS.0000000000002925

30. Atiyeh BS, Fadul R, Chahine F. Cryolipolysis (CLL) for reduction of localized subcutaneous fat: review of the literature and an evidence-based analysis. Aesthet Plast Surg. 2020;44(6):2163–2172. doi:10.1007/s00266-020-01869-x